Asunto(s)
Acetatos/uso terapéutico , Aminas , Analgésicos/uso terapéutico , Anticonvulsivantes/uso terapéutico , Ácidos Ciclohexanocarboxílicos , Neuralgia/tratamiento farmacológico , Ácido gamma-Aminobutírico , Acetatos/administración & dosificación , Acetatos/efectos adversos , Analgésicos/administración & dosificación , Analgésicos/efectos adversos , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/efectos adversos , Neuropatías Diabéticas/tratamiento farmacológico , Gabapentina , Herpes Zóster/complicaciones , Humanos , Neuralgia/diagnóstico , Neuralgia/etiología , Dimensión del Dolor , Satisfacción del Paciente , Factores de TiempoAsunto(s)
Analgésicos Opioides/administración & dosificación , Narcóticos/administración & dosificación , Dolor Postoperatorio/tratamiento farmacológico , Heridas y Lesiones/cirugía , Relación Dosis-Respuesta a Droga , Vías de Administración de Medicamentos , Esquema de Medicación , Combinación de Medicamentos , Humanos , Naloxona/administración & dosificación , Dimensión del Dolor , Tilidina/administración & dosificación , Tramadol/administración & dosificaciónRESUMEN
BACKGROUND AND METHOD: 335 patients (51% female, 49% male, mean age 56 years) with chronic pain and multimorbidity have been included in a multi-center 2-years' study with slow release Tilidine/Naloxone for efficacy and safety which included detailed laboratory examinations. 316 patients had already been treated with analgesics. 159 patients (47.5%) finished the study as planned, 176 patients finished the study earlier. RESULTS: Parameters of quality of life such as persistent pain, sleep, mood and activity have improved. Tolerance has not been observed. In 85 patients (25%) adverse events had occurred (nausea, vomiting, dizziness) which are related to the study-medication. Constipation was documented in only 4 patients. After 2 years of therapy with Tilidine/Naloxone there has been no relevant changes in laboratory findings. There has been no sign of organ damage or interactions with concomitant medication. CONCLUSION: Tilidine/Naloxone is an effective and safe analgesic (WHO II) suitable for the longterm treatment of patients with chronic pain.